Live Breaking News & Updates on Radiopharmaceutical Science

Stay updated with breaking news from Radiopharmaceutical science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Ben Orzelek , Roger Schibli , Julia Hofmann Svenja , Steffen Schuster , European Journal Of Nuclear Medicine , Head Of The Center , Group Leader , Corporate Communications , Research Group Leader , Paul Scherrer Institute , Targeted Radionuclide Therapy , Scherrer Institute , Radiopharmaceutical Science , Radionuclide Therapy , Technologies Munich , European Journal , Nuclear Medicine , Molecular Imaging ,

ITM Isotope Technologies Munich SE: ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

Enhancement of ITM's development and manufacturing activities strengthens ITM's position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 - ITM Isotope ....

Steffen Schuster , Julia Hofmann Svenja , Ben Orzelek , Roger Schibli , Group Leader , Research Group Leader , Head Of The Center , Corporate Communications , European Journal Of Nuclear Medicine , Paul Scherrer Institute , Targeted Radionuclide Therapy , Technologies Munich , Radiopharmaceutical Science , Radionuclide Therapy , European Journal , Nuclear Medicine , Molecular Imaging ,

ITM Enters Cooperation Agreement with Paul Scherrer

Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) . ....

Julia Hofmann Svenja , Steffen Schuster , Ben Orzelek , Roger Schibli , Corporate Communications , European Journal Of Nuclear Medicine , Group Leader , Head Of The Center , Research Group Leader , Paul Scherrer Institute , Targeted Radionuclide Therapy , Scherrer Institute , Radiopharmaceutical Science , Radionuclide Therapy , Technologies Munich , European Journal , Nuclear Medicine , Molecular Imaging , Itm Isotope Technologies Munich Se , Erbium 161 , Licensing Agreement , Precision Oncology , Paul Scherrer Institute ,